Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration
MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri
What it found
The trial ended early for another reason (see below).
This trial finished 15 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- pet-scan FDG-F18
What it measured
Main measures
Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).
At baseline and after 3 months of treatment.
MRI lesionsBrain volume loss
Other measures (1)
Correlation with relapses.
During the 3 months of treatment and the 3 following months.
Relapses
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
* Patients diagnosed with MS * Treatment with Tysabri planned
Exclusion criteria
* Allergy to Tysabri or MRI contrast products * Pregnancy
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the diagnosis value of MRI and positon emission tomography (PET) scan for studying macrophagic infiltration and other brain modification in multiple sclerosis (MS) patients treated with Natalizumab (Tysabri).
Loading reviews and guidelines…
History
Started
Dec 2008
Main results due
Mar 2011
Finished
Mar 2011